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Extending inferences from randomized participants to all
eligible individuals using trials nested within cohort stud-
ies
Abstract
Consider a randomized trial nested within a cohort of eligible individuals, including
those who refused randomization. In this paper, we show how to use baseline covariate
data from the entire cohort, and treatment and outcome data only from randomized
participants, to identify the average causal effect in the target population of all eligible
individuals. We review identifiability conditions and estimators that can be imple-
mented in standard statistical software. We assess the finite-sample performance of
different estimators in simulation studies. Lastly, we apply the estimators in a trial
nested within a cohort study of eligible patients to compare coronary artery bypass
grafting surgery plus medical therapy versus medical therapy alone for patients with
chronic coronary artery disease.
2
1 Background
When effect modifiers influence the decision to participate in clinical trials, inferences
from randomized participants need to be extended (“generalized” or “transported”) to
the population of all eligible individuals [1, 2]. The need to extend trial findings arises
naturally when clinical trials are nested in cohort studies that collect baseline covari-
ate data from all eligible individuals, including those who refused randomization. In
this setting, treatment and follow-up data from non-randomized individuals might be
unavailable or unreliable. For example, investigators might wish to use treatment and
outcome information only from randomized participants to avoid confounding of the
effect of treatment on the outcome among non-randomized individuals [3, 4].
In this paper, we show how baseline covariate data from a cohort of eligible individ-
uals, together with treatment and outcome data exclusively from trial participants, can
be used to estimate the average treatment effect in the target population of all eligible
individuals.
2 Estimands
Let A be the set of treatments evaluated in a randomized trial. For each treatment
a ∈ A, we use the random variable Y a to denote the counterfactual (potential) outcome
under treatment a [5, 6]. Here, we only consider a finite number of distinct treatments
(e.g., comparisons of treatment vs. control, or comparisons between two or more active
treatments). Extensions to continuous treatments are fairly straightforward but are not
pursued here.
Consider a trial nested in a cohort study of eligible individuals, including those
who refused randomization. When baseline covariate information is collected from all
cohort members, but treatment and outcome information is only collected (or only
deemed reliable) from randomized participants, we model the data as independent
and identically distributed realizations of the random vector (Si, Xi, AiSi, YiSi), i =
1, . . . , n, n+ 1, . . . , N , where n is the total number of trial participants; N is the total
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number of individuals meeting the eligibility criteria; S is the indicator for being in
the randomized component of the study (S = 1 for randomized participants; S = 0
for non-randomized eligible individuals); X is a vector of baseline covariates (possibly
high dimensional); A is the (randomized) treatment assignment indicator; and Y is the
observed (post-treatment) outcome. An example data structure for binary treatment
A, along with the potential outcomes, is depicted in Table 1 (we use lower case letters
to denote realizations of random variables).
We are interested in using data from the cohort of eligible individuals, including
data from a randomized sub-cohort, to draw inferences about the target population of
all eligible individuals (the super-population). For any pair of treatments a, a′ ∈ A,
the parameter of interest is the average treatment effect in the target population of all
eligible individuals,
δpop = E[Y a − Y a′ ].
In general, the average treatment effect among all eligible individuals is not equal to
the average treatment effect among randomized participants, that is,
δpop 6= δRCT = E[Y a − Y a′ |S = 1].
In our simplified setup, differences arise when effects are heterogeneous over baseline
covariates that are not equidistributed among trial participants and non-participants [7].
3 Identifiability conditions
We first review the conditions for identifying the components E[Y a|S = 1], a ∈ A,
of the average causal effect in the target population of trial participants. We then
consider additional identifiability conditions for the components E[Y a] of the average
causal effect in the target population of all eligible individuals.
4
3.1 Identifiability conditions for the randomized trial
We can identify the average causal effect in the trial because the following key conditions
are expected to hold [8]:
Consistency of potential outcomes For each person, the observed outcome
under treatment A = a equals the counterfactual outcome Y a. That is,
when Ai = a, Yi = Y ai for every i ∈ {1, . . . , N} and every a ∈ A.
This condition requires that interventions are well-defined, in the sense that they are de-
scribed and operationalized in the trial protocol and applicable to the target population
of all eligible individuals. We consider that each treatment level has a single version,
or, that variation in treatment versions is irrelevant to the counterfactual outcomes [9].
Conditional mean exchangeability The potential outcome mean, conditional
on covariates X, does not depend on treatment assignment among trial participants,
E[Y a|A = a,X, S = 1] = E[Y a|X,S = 1], for every a ∈ A.
Of note, we assume mean exchangeability conditional on covariates in order for our
results to apply to conditionally randomized clinical trials. Marginally randomized
trials are a special case where mean exchangeability holds unconditionally on X.
Positivity of treatment assignment probability The probability of receiving
the compared treatments, conditional on covariates needed to ensure mean exchange-
ability, is bounded away from 0 and 1,
0 < Pr[A = a|X = x, S = 1] < 1, for every a ∈ A
and every x such that fX|S(x|S = 1) > 0.
Finally, we assume that there is no measurement error and no dropouts in the
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trial. These assumptions are often unrealistic in practice and we use them to simplify
exposition. The methods discussed in the next section can be extended to address
measurement error and dropouts; we do not pursue these extensions here to maintain
focus on issues related to extending trial findings.
Given the above conditions and assumptions, the average treatment effect in the
trial can be re-expressed in terms of observed variables,
δRCT = E[Y a − Y a′ |S = 1] = E[Y |A = a, S = 1]− E[Y |A = a′, S = 1],
which can be estimated by the difference of the observed outcome means between
treated and untreated trial participants.
3.2 Identifiability conditions for extending trial findings to
the target population
We need the following additional conditions to identify E[Y a]:
Conditional mean transportability Conditional on covariates, participation in
the trial does not influence the potential outcome mean under treatment a,
E[Y a|X,S = 1] = E[Y a|X], for every a ∈ A.
This condition connects the counterfactual outcome mean in the population of trial
participants to the mean in the target population of all eligible individuals.
Positivity of trial participation The probability of trial participation, condi-
tional on covariates needed for mean transportability, is bounded away from 0,
Pr[S = 1|X = x] > 0, for every x such that fX(x) > 0.
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Note that, in contrast to the probability of treatment assignment, the probability of
trial participation does not need to be bounded away from 1.
4 Estimators for extending trial results to the tar-
get population of all eligible individuals
When baseline covariate data are available from the entire cohort of eligible individuals,
but treatment and outcome data is only available from non-randomized individuals, we
view the problem of extending inferences from randomized participants to the target
population of all eligible individuals as a missing data problem. Specifically, the trial
participation indicator, S, serves as a missing data indicator for the observed outcome
(and thus, also for all potential outcomes). Using the consistency condition, the product
of the trial participation and treatment indicators, SI(A = a), serves as a missing data
indicator for the potential outcome under treatment a.
This perspective highlights connections between different methods for extending
trial findings to the target population [10, 11] and suggests estimators with improved
efficiency and robustness to model misspecification. In this section, we discuss three
types of estimators: (1) outcome model-based estimators that rely on modeling the ex-
pectation of the outcome; (2) inverse probability (IP) weighting estimators that rely on
modeling the probability of participation in the trial; and (3) doubly robust estimators
that rely on modeling the expectation of the outcome and the probability of participa-
tion in the trial. We provide derivations of the asymptotic behavior of these estimators
in the Appendix; hereafter, “convergence” and the symbol “→” denote convergence in
probability; estimators that converge to their estimands are termed “consistent”.
4.1 Outcome model-based estimator
The outcome model-based estimator is an application of the parametric G-formula for
point exposures [12]. The estimator is obtained by marginalizing a conditional outcome
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mean model over the empirical distribution of covariates of eligible individuals,
µˆOM =
1
N
N∑
i=1
ga(Xi; γˆ), (1)
where ga(Xi; γˆ), is an estimated conditional outcome mean model (with parameter γ)
for each treatment a. When the model is correctly specified,
ga(Xi; γˆ)→ E[Y |A = a,X, S = 1] for every a ∈ A,
and, provided the identifiability conditions hold, µˆOM → E[Y a].
4.2 IP weighting estimator
The probability of participation in the trial can be used to estimate the treatment effect
in the target population of all eligible individuals using IP weighting, an approach re-
lated to methods for survey analyses [13] and the use of inverse probability of treatment
weighting to address confounding in observational studies [14].
When trials nested within cohorts of eligible individduals, we do not know the
“true” probability of participation, but we can estimate it. Using wa(Xi; βˆ) to denote
the estimated probability of participating in the trial and being assigned to treatment
a, for every a ∈ A, we construct the following inverse probability weighted estimator of
the average causal effect in the target population:
µˆIPW =
1
N
N∑
i=1
SiI(Ai = a)Yi
wa(Xi; βˆ)
. (2)
When the model for the probability of participation is correctly specified,
wa(Xi; βˆ)→ Pr[S = 1|X]Pr[A = a|X,S = 1] for every a ∈ A,
and, provided the identifiability conditions hold, µˆIPW → E[Y a]. Note that the probabil-
ity of treatment in the trial Pr[A = a|X,S = 1] is under the control of the investigators
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and does not need to be estimated. Nevertheless, estimating that component of the
weight can “adjust” for any imbalances in the distribution of observed covariates among
trial participants.
4.3 Doubly robust estimators
When X is high dimensional or contains continuous components, investigators using
the outcome model-based and IP weighting estimators have to respectively rely on
parametric working models for the expectation of the outcome and the probability of
participation in the trial. In most practical cases, background knowledge will be inad-
equate for correctly specifying these models and misspecification will lead to estimator
inconsistency. We can improve robustness to misspecification by combining the two
models to obtain doubly robust estimators; these estimators can be viewed as efficient
(augmented) versions of the IP weighting estimator [15]. The theory of doubly robust
estimation is extensive and multiple estimators, with different behavior in finite sam-
ples, are doubly robust [16, 17]. Here, we examine two estimators that are easy to
implement in standard statistical packages.
First, we can obtain a substitution doubly robust estimator
µˆDR1 =
1
N
N∑
i=1
{
SiI(Ai = a)Yi
wa(Xi; βˆ)
+
wa(Xi; βˆ)− SiI(Ai = a)
wa(Xi; βˆ)
ga(Xi; γˆ)
}
, (3)
with wa(Xi; βˆ) and ga(Xi; γˆ) as defined above.
Second, we can obtain a regression-based doubly robust estimator by fitting an in-
verse probability weighted regression model for the outcome, ga(Xi; γ∗), a ∈ A, and
then marginalizing the predictions from the regression model over the covariate distri-
bution of all eligible individuals,
µˆDR2 =
1
N
N∑
i=1
ga(Xi; γ̂
∗), (4)
where γ̂∗ is the vector of estimated parameters from the weighted outcome regression.
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This estimator is doubly robust when the outcome is modeled with a linear exponential
family [18] quasi-likelihood and the canonical link function [17, 19]. Unlike the substi-
tution estimator in Equation (3), the weighted regression estimator in Equation (4) is
bounded (estimates fall within the support of the outcome’s probability distribution).
Boundedness is an attractive property when the inverse probability of participation
weights are highly variable [17]. In finite samples, doubly robust estimators will tend
to produce more precise results than the IP weighting estimator.
5 Simulation studies
We conducted a simulation study to compare the finite-sample performance of different
estimators for the average treatment effect in the population of eligible individuals.
In this section, we describe simulation methods and results for continuous outcomes;
information on binary outcomes is presented in the Appendix, along with computer
code to replicate the analyses.
5.1 Data generation
We run a factorial simulation experiment using 2 cohort sample sizes (N) × 3 trial
participant proportions (Pr[S = 1]) × 4 main treatment effects (τ) × 3 magnitudes of
departure from additive effects (ψ), resulting in a total of 72 scenarios for the continuous
outcome simulation study.
Figure 1 is a directed acyclic graph for the data generation. We first generated
baseline covariates Xj,i ∼ N (0, 1) with j = 1, 2, 3; i = 1, ..., N , where N is the number
of eligible individuals, including those not participating in the randomized trial. In
different scenarios, N was 100,000 or 1,000,000.
We “selected” trial participants using a logistic linear model,
Pr[Si = 1|Xi] = exp(Xiθ)/(1 + exp(Xiθ)),
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where θT = (θ0, 1, 1, 1) and Xi = (1, X1,i, . . . , X3,i). The intercept θ0 was chosen for
each N such that it resulted in average trial sizes of 1000 , 5000, or 10000 participants.
We then generated an indicator of unconditional treatment assignment, A, among trial
participants using a Bernoulli distribution with parameter Pr[A = 1|S = 1] = 0.5.
Finally, we generated outcomes using the linear model
Yi = τAi + ψX1,iAi +Xiζ + i,
where τ is the main treatment effect, ψ determines the magnitude of effect modification
by X1, ζT = (−3, 1, 1, 1), and i ∼ N (0, 0.5). We ran scenarios with different levels of
effect modification (ψ set to 0, 1, or 2) and different main treatment effects (τ set to 0, 1,
2 or 3). In each simulated dataset, we applied the estimators in Equations (1) through
(4), and also obtained a trial-only estimate of the treatment effect. All working models
required for the different estimators were correctly specified. We estimated the bias,
variance, and mean squared error of the estimators over 1000 runs for each scenario.
5.2 Simulation results
The complete simulation results for the continuous outcome simulation study are pro-
vided in Appendix Tables A.1 to A.6; Figures 2 and 3 present results for the continuous
outcome using N = 100, 000. When all models were correctly specified, all estima-
tors were approximately unbiased. The outcome-model based estimator had the low-
est variance, followed closely by the two doubly robust estimators. The IP weighting
estimator had substantially larger variance than all other estimators; that variance,
though, became smaller as we increased N and n. As expected, in the presence of
effect modification, the trial-only estimator gave very different results compared to the
estimators in Equations (1) through (4). The trial-only estimator is, of course, unbi-
ased for E[Y 1 − Y 0|S = 1] under very general conditions, but biased for E[Y 1 − Y 0]
when selection into the trial depends on the effect modifier. Results from simulations
with larger sample size and binary outcomes were qualitatively similar in terms of all
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performance measures (see Appendix Tables A.1 to A.6 and A.8 to A.13).
6 The Coronary Artery Surgery Study (CASS)
The CASS compared coronary artery bypass grafting surgery plus medical therapy
(henceforth, “surgery”) versus medical therapy alone for patients with chronic coronary
artery disease. Of 2099 eligible patients, 780 consented to randomization and 1319
declined. Details about the design of the CASS are available elsewhere [20, 21]. No
patients were lost to follow-up in the first 10 years of the study.
We implemented the methods from Section 4 to estimate the 10-year mortality risk
(cumulative incidence proportion) under surgery and medical therapy, and the risk
difference and risk ratio comparing the treatments for all eligible patients, including
those who did not consent to randomization.
We fit logistic regression models for the probability of participation in the trial and
the probability of the outcome with the following covariates: age, severity of angina,
history of previous myocardial infarction, percent obstruction of the proximal left an-
terior descending artery, left ventricular wall motion score, number of diseased vessels,
and ejection fraction. We chose these variables based on a previous publication analyz-
ing the same data [22] and we did not perform any model specification search. Of the
2099 patients, 1688 had complete data on all baseline covariates (733 randomized, 369
in the surgery group and 364 in the medical therapy group; 955 non-randomized); for
simplicity, we restricted our analyses to patients with complete data. We used boot-
strap resampling (10,000 samples) to obtain percentile 95% confidence intervals (normal
distribution-based bootstrap intervals were nearly identical and are not shown).
Estimates of the 10-year mortality risk and treatment effects at 10 years are shown
in Table 2. All methods produced similar results: the mortality rate in the target
population was estimated to be about 18% for surgery and 20% for medical therapy,
corresponding to a risk difference of about 2% and a risk ratio of about 0.9, in favor
of surgery. Since different methods rely on different parametric models, concordance
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across methods suggests that inference on the treatment effect in the target population
is not driven by model specification.
7 Discussion
In this paper, we examined methods for extending inferences from randomized partici-
pants to the population of all eligible individuals, including those who decline random-
ization, using only baseline covariate data on eligible non-randomized individuals from
randomized trials nested within cohort studies. Our work adds to the recent literature
on “transportability” [10,23–29] by more thoroughly considering issues related to model
specification and the comparative performance of different estimators in finite samples.
7.1 Identifiability conditions and the utility of the pro-
posed methods
The methods we propose rest on two strong and untestable identifiability conditions
beyond those ensured by randomization: (1) trial participants and non-participants are
exchangeable in mean, conditional on baseline covariates; and (2) no pattern of the
covariates needed for transportability makes trial participation impossible. Directed
acyclic graphs can greatly facilitate reasoning about these conditions [30–33].
Arguably, the conditions are most plausible in studies explicitly designed to collect
information on all eligible individuals, including those who do not consent to randomiza-
tion. Our methods, then, are well-suited to “comprehensive cohort studies” [22,34,35],
randomized preference designs [3,36], and pragmatic trials embedded within healthcare
systems [37–39]. Applied to data from these designs, the methods provide “best guesses”
about the treatment effect in the target population of all eligible patients. Even if not
deemed credible enough for clinical decision-making, such estimates can be useful for
designing future studies (e.g., as inputs for power calculations).
Our approach uses treatment and outcome data only from randomized participants,
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to avoid confounding of the effect of treatment on the outcome among non-randomized
patients. As an added benefit, this eliminates the need to follow-up patients who decline
randomization. Nevertheless, if treatment and outcome data from non-randomized
patients are available, it is useful to compare the results from our analyses, which require
conditional mean transportability from randomized to non-randomized patients, against
the results of observational analyses of the entire cohort, which require conditional mean
exchangeability of treated and untreated non-randomized patients. These analyses
target the same estimand but rest on different identifiability conditions; thus, agreement
between them provides mutual support for their validity and disagreement can suggest
avenues for exploring effect modification or addressing biases in future studies.
By explicitly considering the identifiability conditions necessary for extending trial
findings from randomized participants to the population of all eligible individuals, we
can begin to develop quantitative methods for sensitivity analysis that would reveal the
impact of possible violations of the conditions on results [40]. Work in this direction has
began [41] and the connection with missing data theory may prove even more fruitful
in the future [42].
7.2 Model specification and robustness
All methods for extending inferences from randomized participants to the target pop-
ulation of all eligible individuals exploit models for the expectation of the outcome or
the probability of trial participation. Investigators have to rely on parametric work-
ing versions of these models whenever the vector of covariates necessary to satisfy the
conditional mean transportability condition is high-dimensional or contains continuous
components. Even if conditional mean transportability holds, misspecification of the
outcome or participation model can lead to inconsistency of the corresponding estima-
tor.
Doubly robust estimators are consistent when either working model is correctly
specified, providing two opportunities for valid inference. In finite samples, however,
misspecification of just one of the models, can adversely affect how these estimators
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perform. And misspecification of both models, in rare cases, can make them perform
worse than the outcome model-based estimator [43]. Serious bias can also occur when
inverse probability weights exhibit high variance, though this problem is mitigated to
some extent with bounded estimators [17], such as the estimator in Equation (4).
In practice, correct specification of the outcome model is impossible when outcomes
are influenced by unknown or known-but-unmeasured factors. Approximately correct
specification of the model for the probability of participation may be more feasible,
because we can use surveys or qualitative studies to investigate what drives eligible
individuals to participate in a randomized trial [44]. We can use the findings of these
investigations to specify (approximately) correct models for trial participation and ob-
tain consistent IP weighting estimators. Yet, even when the outcome model is known
to be misspecified, doubly robust estimators may still be preferred for their (typically)
smaller sampling variance.
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9 Tables
Table 1: Data structure including trial participants (S = 1) and non-randomized individuals
(S = 0) for a binary treatment (A). Y is the observed outcome, and X is a vector of baseline
covariates. Y 1 and Y 0 are potential outcomes under treatment a = 1 and a = 0, respectively.
Dashes denote missing data.
S A Y 1 Y 0 Y X
1 1 y11 y01 y1 = y11 x1
1 1 y12 y02 y2 = y12 x2
...
...
...
...
...
...
1 1 y1m y0m ym = y1m xm
1 0 y1m+1 y0m+1 ym+1 = y0m+1 xm+1
1 0 y1m+2 y0m+2 ym+2 = y0m+1 xm+2
... 0
...
...
...
...
1 0 y1n y0n yn = y0n xn
0 − y1n+1 y0n+1 − xn+1
0 − y1n+2 y0n+2 − xn+2
...
...
...
...
...
...
0 − y1N y0N − xN
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10 Figures
Figure 1: Directed acyclic graph for the data generation in the simulation study.
A YS = 1
X1, X2, X3
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Figure 2: Simulation study: bias of estimators across different main treatment effects (τ),
magnitudes of effect modification (ψ), and trial sample sizes (n), for N = 100, 000.
-0.1
0.0
0.1
Bi
as
0 1 2 3
γ  
n = 1000, ψ = 0
-0.1
0.0
0.1
  
0 1 2 3
γ  
n = 5000, ψ = 0
-0.1
0.0
0.1
  
0 1 2 3
γ  
n = 10,000, ψ = 0
-0.1
0.0
0.1
Bi
as
0 1 2 3
γ
n = 1000, ψ = 1
-0.1
0.0
0.1
  
0 1 2 3
γ
n = 5000, ψ = 1
-0.1
0.0
0.1
  
0 1 2 3
γ
n = 10,000, ψ = 1
-0.1
0.0
0.1
Bi
as
0 1 2 3
γ  
n = 1000, ψ = 2
-0.1
0.0
0.1
  
0 1 2 3
γ  
n = 5000, ψ = 2
-0.1
0.0
0.1
  
0 1 2 3
γ  
n = 10,000, ψ = 2
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Figure 3: Simulation study: variance of estimators across different main treatment effects
(τ), magnitudes of effect modification (ψ), and trial sample sizes (n), for N = 100, 000.
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Appendix
Derivations for estimator consistency
We derive the key results referred to in the main text of the paper by showing that the
proposed estimators are consistent estimators for the mean of the potential outcome
distribution under A = a, which implies that the estimators can be used to estimate
all commonly used marginal measures of the treatment effect (e.g., the causal risk
difference, relative risk, or odds ratio) [45]. We do not dwell on technical conditions
that are needed to render our results rigorous. Interested readers can refer to the books
by Van der Laan and Robins [46] and Tsiatis [47] for more complete treatments of
missing data and causal inference problems.
Outcome model-based estimator
The outcome model-based estimator of the potential outcome mean is
µˆOM =
1
N
N∑
i=1
ga(Xi; γˆ),
where ga(Xi; γˆ) is an estimator of a model for the expectation of the outcome. In
large samples the estimator converges to a limiting value, ga(Xi; γ∗); if the model is
correctly specified, then
ga(Xi; γˆ)→ ga(Xi; γ∗) = E[Y |A = a,X, S = 1].
It follows that in large samples, when the outcome model is correctly specified the
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estimator converges to the potential outcome mean,
µˆOM → E[ga(Xi; γ∗)]
= EX [E[Y |A = a,X, S = 1]]
(1)
= EX [E[Y a|A = a,X, S = 1]]
(2)
= EX [E[Y a|X,S = 1]]
(3)
= EX [E[Y a|X]]
(4)
= E[Y a],
where equality (1) is by the consistency condition, (2) is by conditional mean exchange-
ability in the trial, (3) is by conditional mean transportability, and (4) is by the law of
iterated expectation.
Inverse probability (IP) weighting estimator
The IP weighting estimator of the potential outcome mean is
µˆIPW =
1
N
N∑
i=1
SiI(Ai = a)Yi
wa(Xi; βˆ)
,
where wa(Xi; βˆ) is an estimator of a model for the probability of participation in
the trial times the probability of receiving treatment A = a among trial participants.
In large samples wa(Xi; βˆ) converges to a limiting value, wa(Xi;β∗); if the model is
correctly specified,
wa(Xi; βˆ)→ wa(Xi;β∗) = Pr[S = 1|X] Pr[A = a|X,S = 1].
It follows that, in large samples when the probability of participation model is
correctly specified, the IP weighiting estimator converges to the potential outcome
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mean,
µˆIPW → E
[
SI(A = a)Y
wa(X;β∗)
]
(1)
= EX
[
E
[
SI(A = a)Y
wa(X;β∗)
|X
]]
= EX
[
1
wa(X;β∗)
E [SI(A = a)Y |X]
]
= EX
[
1
wa(X;β∗)
E [Y |A = a,X, S = 1]Pr[S = 1|X] Pr[A = a|X,S = 1]
]
(2)
= EX [E [Y |A = a,X, S = 1]]
(3)
= E[Y a],
where equality (1) is by the law of iterated expectation, (2) is by the construction of
the weights, and (3) follows from the derivation for the outcome model-based estimator.
Doubly robust estimators
Substitution estimator
Our approach here is similar to the treatment of doubly robust estimation for con-
founding control (e.g., [47]). First, re-write the doubly robust estimator of the potential
outcome mean as
µˆDR1 =
1
N
N∑
i=1
{
SiI(Ai = a)Yi
wa(Xi; βˆ)
+
wa(Xi; βˆ)− SiI(Ai = a)
wa(Xi; βˆ)
ga(Xi; γˆ)
}
=
1
N
N∑
i=1
SiI(Ai = a)Yi
wa(Xi, βˆ)
+
1
N
N∑
i=1
ga(Xi; γˆ)− 1
N
N∑
i=1
SiI(Ai = a)
wa(Xi, βˆ)
ga(Xi; γˆ),
where, as above, ga(Xi; γˆ) is fitted model for the expectation of the outcome and
wa(Xi; βˆ) is a fitted model for the probability of participation in the trial times the
probability of receiving treatment A = a among trial participants.
We now examine cases.
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Case 1: correct specification of wa(Xi; β); incorrect specification of
ga(Xi; γ). As noted above, in large samples, estimators for the parameters of the
outcome model and probability of participation models converge to the limiting values,
ga(Xi; γ
∗) and wa(Xi;β∗), respectively. If the probability of participation model is
correctly specified but the outcome model is incorrectly specified, we have
wa(Xi; βˆ)→ wa(Xi;β∗) = Pr[S = 1|X] Pr[A = a|X,S = 1], but
ga(Xi; γˆ)→ ga(Xi; γ∗) 6= E[Y |A = a,X, S = 1].
Under these conditions, the estimator is consistent,
µˆDR1 → E
[
SI(A = a)Y
wa(X;β∗)
]
+ E[ga(X; γ∗)]− E
[
SI(A = a)ga(X; γ
∗)
wa(X;β∗)
]
(1)
= E[Y a] + E[ga(X; γ∗)]− E
[
SiAiga(X; γ
∗)
wa(X;β∗)
]
(2)
= E[Y a] + E[ga(X; γ∗)]− EX
[
ga(X; γ
∗)
wa(X;β∗)
E [SI(A = a)|X]
]
(3)
= E[Y a] + E[ga(X; γ∗)]− E
[
ga(X; γ
∗)
wa(X;β∗)
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
= E[Y a] + E[ga(X; γ∗)]− E[ga(X; γ∗)]
= E[Y a],
where equality (1) follows from our derivation for the IP weighting estimator, (2) from
the law of iterated expectation, and (3) from the definition of the weights.
Case 2: correct specification of ga(Xi; γ); incorrect specification of
wa(Xi; β). If the outcome model is correctly specified but the probability of par-
ticipation model is not, we have
ga(Xi; γˆ)→ ga(Xi; γ∗) = E[Y |A = a,X, S = 1], but
wa(Xi; βˆ)→ wa(Xi;β∗) 6= Pr[S = 1|X] Pr[A = a|X,S = 1].
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Yet, the estimator will remain consistent,
µˆDR1 → E
[
SI(A = a)Y
wa(X;β∗)
]
+ E[ga(X; γ∗)]− E
[
SI(A = a)ga(X; γ
∗)
wa(X;β∗)
]
(1)
= E
[
SI(A = a)Y
wa(X;β∗)
]
+ E[Y a]− E
[
SI(A = a)ga(X; γ
∗)
wa(X;β∗)
]
(2)
= EX
[
E
[
SI(A = a)Y
wa(X;β∗)
|X
]]
+ E[Y a]− EX
[
E
[
SI(A = a)ga(X; γ
∗)
wa(X;β∗)
|X
]]
= EX
[
Pr[S = 1|X] Pr[A = a|X,S = 1]
wa(X;β∗)
E[Y |A = a,X, S = 1]
]
+ E[Y a]
−EX
[
ga(X; γ
∗)
wa(X;β∗)
E [SI(A = a)|X]
]
(3)
= EX
[
Pr[S = 1|X] Pr[A = a|X,S = 1]
wa(X;β∗)
E[Y |A = a,X, S = 1]
]
+ E[Y a]
−EX
[
ga(X; γ
∗)
wa(X;β∗)
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
= E[Y a],
where equality (1) follows from our derivation for the outcome model-based estimator,
(2) from the law of iterated expectation, and (3) from the definition of the outcome
model.
From Cases 1 and 2 it also follows that the doubly robust estimator is also consistent
when both the outcome and probability of participation models are correct.
Weighted regression estimator
The consistency and double robustness properties of the weighted regression based
estimator follows from properties of quasi-likelihood estimation in the linear exponential
families [18] and standard weighted optimization arguments [19].
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Additional results for the continuous outcome simulation
study
Table A.1: Bias of estimators across different main treatment effects (τ), magnitudes of effect
modification (ψ), and trial sample sizes (n), for the continuous outcom with N = 100, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0 0 1000 0.002 0.001 -0.003 0.001 0.001
2 0 0 5000 0.000 0.001 -0.018 0.000 0.001
3 0 0 10000 0.001 0.001 0.005 0.001 0.001
4 0 1 1000 0.919 0.001 0.011 0.007 0.006
5 0 1 5000 0.780 0.001 0.002 0.002 0.001
6 0 1 10000 0.685 0.000 0.018 0.000 0.000
7 0 2 1000 1.828 0.003 0.038 0.001 0.001
8 0 2 5000 1.562 0.001 0.006 0.002 0.002
9 0 2 10000 1.374 0.001 0.003 0.001 0.000
10 1 0 1000 0.000 0.001 0.036 0.005 0.003
11 1 0 5000 0.001 0.001 0.011 0.002 0.002
12 1 0 10000 0.001 0.000 0.003 0.001 0.001
13 1 1 1000 0.907 0.000 0.038 0.003 0.002
14 1 1 5000 0.781 0.000 0.021 0.001 0.000
15 1 1 10000 0.687 0.001 0.020 0.001 0.002
16 1 2 1000 1.826 0.003 0.018 0.002 0.001
17 1 2 5000 1.565 0.000 0.014 0.000 0.000
18 1 2 10000 1.373 0.000 0.019 0.001 0.000
19 2 0 1000 0.000 0.000 0.034 0.002 0.000
20 2 0 5000 0.001 0.001 0.020 0.000 0.001
21 2 0 10000 0.000 0.000 0.007 0.000 0.000
22 2 1 1000 0.913 0.003 0.031 0.000 0.001
23 2 1 5000 0.783 0.000 0.001 0.001 0.000
24 2 1 10000 0.689 0.000 0.001 0.000 0.000
25 2 2 1000 1.821 0.001 0.032 0.004 0.002
26 2 2 5000 1.560 0.000 0.007 0.004 0.003
27 2 2 10000 1.376 0.000 0.009 0.001 0.001
28 3 0 1000 0.000 0.002 0.011 0.005 0.003
29 3 0 5000 0.002 0.001 0.005 0.001 0.001
30 3 0 10000 0.001 0.001 0.008 0.002 0.002
31 3 1 1000 0.917 0.001 0.020 0.001 0.002
32 3 1 5000 0.782 0.001 0.019 0.001 0.001
33 3 1 10000 0.688 0.001 0.007 0.000 0.000
34 3 2 1000 1.822 0.001 0.042 0.003 0.000
35 3 2 5000 1.566 0.001 0.025 0.001 0.001
36 3 2 10000 1.374 0.000 0.010 0.001 0.000
Results are presented for the following estimators: Trial, unadjusted, using only trial partic-
ipants; OM, outcome model-based; IPW, inverse probability weighting; DR1, substitution
doubly robust; DR2, weighted regression doubly robust.
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Table A.2: Variance of estimators across different main treatment effects (τ), magnitudes
of effect modification (ψ), and trial sample sizes (n), for the continuous outcome with N =
100, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0 0 1000 0.011 0.004 0.392 0.016 0.011
2 0 0 5000 0.002 0.001 0.117 0.004 0.002
3 0 0 10000 0.001 0.000 0.040 0.001 0.001
4 0 1 1000 0.016 0.004 0.594 0.015 0.011
5 0 1 5000 0.003 0.001 0.146 0.003 0.002
6 0 1 10000 0.001 0.000 0.057 0.001 0.001
7 0 2 1000 0.024 0.004 0.783 0.018 0.010
8 0 2 5000 0.004 0.001 0.191 0.003 0.002
9 0 2 10000 0.002 0.000 0.125 0.001 0.001
10 1 0 1000 0.011 0.004 0.351 0.016 0.011
11 1 0 5000 0.002 0.001 0.096 0.003 0.002
12 1 0 10000 0.001 0.000 0.041 0.001 0.001
13 1 1 1000 0.016 0.004 0.511 0.013 0.010
14 1 1 5000 0.003 0.001 0.148 0.003 0.002
15 1 1 10000 0.001 0.000 0.060 0.001 0.001
16 1 2 1000 0.024 0.004 0.712 0.016 0.011
17 1 2 5000 0.004 0.001 0.186 0.003 0.002
18 1 2 10000 0.002 0.000 0.076 0.001 0.001
19 2 0 1000 0.011 0.004 0.374 0.016 0.011
20 2 0 5000 0.002 0.001 0.101 0.003 0.002
21 2 0 10000 0.001 0.000 0.037 0.001 0.001
22 2 1 1000 0.017 0.003 0.519 0.015 0.010
23 2 1 5000 0.003 0.001 0.124 0.003 0.002
24 2 1 10000 0.001 0.000 0.059 0.001 0.001
25 2 2 1000 0.024 0.004 0.708 0.016 0.011
26 2 2 5000 0.005 0.001 0.197 0.003 0.002
27 2 2 10000 0.002 0.000 0.087 0.001 0.001
28 3 0 1000 0.010 0.004 0.365 0.015 0.010
29 3 0 5000 0.002 0.001 0.090 0.003 0.002
30 3 0 10000 0.001 0.000 0.046 0.001 0.001
31 3 1 1000 0.016 0.004 0.508 0.016 0.010
32 3 1 5000 0.003 0.001 0.133 0.003 0.002
33 3 1 10000 0.001 0.000 0.064 0.001 0.001
34 3 2 1000 0.022 0.004 0.742 0.015 0.011
35 3 2 5000 0.004 0.001 0.176 0.002 0.002
36 3 2 10000 0.002 0.000 0.081 0.001 0.001
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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Table A.3: Mean square error of estimators across different main treatment effects (τ),
magnitudes of effect modification (ψ), and trial sample sizes (n), for the continuous outcome
with N = 100, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0 0 1000 0.011 0.004 0.392 0.016 0.011
2 0 0 5000 0.002 0.001 0.117 0.004 0.002
3 0 0 10000 0.001 0.000 0.040 0.001 0.001
4 0 1 1000 0.860 0.004 0.594 0.015 0.011
5 0 1 5000 0.610 0.001 0.146 0.003 0.002
6 0 1 10000 0.471 0.000 0.057 0.001 0.001
7 0 2 1000 3.367 0.004 0.784 0.018 0.010
8 0 2 5000 2.444 0.001 0.191 0.003 0.002
9 0 2 10000 1.891 0.000 0.125 0.001 0.001
10 1 0 1000 1.012 1.006 1.279 1.006 1.005
11 1 0 5000 1.004 1.003 1.119 1.007 1.007
12 1 0 10000 1.000 1.000 1.036 0.999 0.999
13 1 1 1000 3.652 1.004 1.587 1.018 1.014
14 1 1 5000 3.175 1.001 1.106 1.001 1.002
15 1 1 10000 2.847 0.999 1.021 0.999 0.998
16 1 2 1000 8.007 1.009 1.675 1.012 1.009
17 1 2 5000 6.582 1.000 1.214 1.003 1.003
18 1 2 10000 5.635 1.000 1.039 1.000 1.000
19 2 0 1000 4.012 4.003 4.238 4.006 4.010
20 2 0 5000 4.005 4.003 4.184 4.003 4.008
21 2 0 10000 3.999 3.999 4.067 4.002 4.001
22 2 1 1000 8.505 3.994 4.645 4.015 4.007
23 2 1 5000 7.750 4.002 4.129 4.005 4.002
24 2 1 10000 7.234 4.000 4.063 4.003 4.002
25 2 2 1000 14.625 4.001 4.838 4.002 4.002
26 2 2 5000 12.680 3.999 4.170 3.987 3.989
27 2 2 10000 11.399 3.999 4.124 3.997 3.998
28 3 0 1000 9.011 9.016 9.297 9.047 9.027
29 3 0 5000 9.015 9.007 9.120 9.011 9.005
30 3 0 10000 9.007 9.006 8.998 9.012 9.011
31 3 1 1000 15.357 9.008 9.628 9.009 8.999
32 3 1 5000 14.307 9.008 9.250 9.012 9.010
33 3 1 10000 13.607 8.998 9.107 9.002 9.002
34 3 2 1000 23.272 9.008 9.995 8.997 9.009
35 3 2 5000 20.853 9.006 9.326 9.009 9.007
36 3 2 10000 19.135 8.997 9.141 8.996 8.998
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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Table A.4: Bias of estimators across different main treatment effects (τ), magnitudes of effect
modification (ψ), and trial sample sizes (n), for the continuous outcome with N = 1, 000, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0 0 1000 0.001 0.001 0.003 0.002 0.001
2 0 0 5000 0.000 0.002 0.002 0.002 0.002
3 0 0 10000 0.001 0.000 0.012 0.000 0.000
4 0 1 1000 0.968 0.002 0.020 0.008 0.005
5 0 1 5000 0.926 0.000 0.009 0.002 0.002
6 0 1 10000 0.890 0.000 0.000 0.000 0.000
7 0 2 1000 1.951 0.003 0.025 0.002 0.004
8 0 2 5000 1.850 0.000 0.011 0.002 0.000
9 0 2 10000 1.784 0.000 0.013 0.000 0.000
10 1 0 1000 0.002 0.001 0.016 0.002 0.000
11 1 0 5000 0.001 0.001 0.008 0.001 0.001
12 1 0 10000 0.000 0.001 0.001 0.001 0.000
13 1 1 1000 0.974 0.003 0.005 0.002 0.001
14 1 1 5000 0.926 0.001 0.008 0.000 0.000
15 1 1 10000 0.892 0.001 0.013 0.001 0.001
16 1 2 1000 1.954 0.001 0.009 0.004 0.003
17 1 2 5000 1.852 0.001 0.009 0.001 0.001
18 1 2 10000 1.781 0.000 0.030 0.001 0.001
19 2 0 1000 0.002 0.003 0.013 0.008 0.006
20 2 0 5000 0.001 0.000 0.003 0.000 0.000
21 2 0 10000 0.001 0.002 0.003 0.001 0.001
22 2 1 1000 0.973 0.001 0.024 0.001 0.001
23 2 1 5000 0.927 0.001 0.003 0.001 0.001
24 2 1 10000 0.890 0.000 0.010 0.002 0.002
25 2 2 1000 1.945 0.001 0.053 0.001 0.001
26 2 2 5000 1.853 0.000 0.006 0.001 0.002
27 2 2 10000 1.781 0.000 0.014 0.001 0.001
28 3 0 1000 0.000 0.000 0.025 0.004 0.002
29 3 0 5000 0.001 0.000 0.006 0.001 0.000
30 3 0 10000 0.000 0.000 0.001 0.001 0.001
31 3 1 1000 0.980 0.001 0.035 0.001 0.001
32 3 1 5000 0.927 0.002 0.009 0.000 0.001
33 3 1 10000 0.890 0.000 0.003 0.000 0.000
34 3 2 1000 1.950 0.000 0.005 0.001 0.000
35 3 2 5000 1.848 0.001 0.015 0.000 0.001
36 3 2 10000 1.782 0.000 0.031 0.001 0.001
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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Table A.5: Variance of estimators across different main treatment effects (τ), magnitudes
of effect modification (ψ), and trial sample sizes (n), for the continuous outcome with N =
1, 000, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0 0 1000 0.007 0.002 0.300 0.010 0.007
2 0 0 5000 0.001 0.000 0.081 0.002 0.002
3 0 0 10000 0.001 0.000 0.042 0.001 0.001
4 0 1 1000 0.010 0.002 0.462 0.011 0.007
5 0 1 5000 0.002 0.001 0.124 0.002 0.002
6 0 1 10000 0.001 0.000 0.063 0.001 0.001
7 0 2 1000 0.016 0.002 0.490 0.010 0.007
8 0 2 5000 0.003 0.001 0.148 0.002 0.002
9 0 2 10000 0.002 0.000 0.101 0.001 0.001
10 1 0 1000 0.007 0.002 0.298 0.011 0.007
11 1 0 5000 0.001 0.000 0.075 0.002 0.002
12 1 0 10000 0.001 0.000 0.046 0.001 0.001
13 1 1 1000 0.011 0.002 0.413 0.011 0.007
14 1 1 5000 0.002 0.000 0.128 0.002 0.002
15 1 1 10000 0.001 0.000 0.056 0.001 0.001
16 1 2 1000 0.016 0.002 0.586 0.013 0.008
17 1 2 5000 0.003 0.001 0.148 0.002 0.002
18 1 2 10000 0.002 0.000 0.085 0.001 0.001
19 2 0 1000 0.007 0.002 0.260 0.009 0.007
20 2 0 5000 0.001 0.000 0.075 0.002 0.002
21 2 0 10000 0.001 0.000 0.048 0.001 0.001
22 2 1 1000 0.011 0.002 0.380 0.009 0.007
23 2 1 5000 0.002 0.001 0.138 0.002 0.002
24 2 1 10000 0.001 0.000 0.062 0.001 0.001
25 2 2 1000 0.016 0.002 0.546 0.009 0.008
26 2 2 5000 0.003 0.000 0.166 0.002 0.002
27 2 2 10000 0.002 0.000 0.078 0.001 0.001
28 3 0 1000 0.007 0.002 0.288 0.012 0.008
29 3 0 5000 0.001 0.000 0.083 0.002 0.002
30 3 0 10000 0.001 0.000 0.045 0.001 0.001
31 3 1 1000 0.011 0.002 0.383 0.011 0.007
32 3 1 5000 0.002 0.000 0.108 0.002 0.002
33 3 1 10000 0.001 0.000 0.066 0.001 0.001
34 3 2 1000 0.015 0.002 0.627 0.011 0.008
35 3 2 5000 0.003 0.000 0.198 0.002 0.002
36 3 2 10000 0.002 0.000 0.086 0.001 0.001
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
35
Table A.6: Mean square error of estimators across different main treatment effects (τ),
magnitudes of effect modification (ψ), and trial sample sizes (n), for the continuous outcome
with N = 1, 000, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0 0 1000 0.007 0.002 0.300 0.010 0.007
2 0 0 5000 0.001 0.000 0.081 0.002 0.002
3 0 0 10000 0.001 0.000 0.042 0.001 0.001
4 0 1 1000 0.946 0.002 0.462 0.011 0.007
5 0 1 5000 0.859 0.001 0.124 0.002 0.002
6 0 1 10000 0.794 0.000 0.063 0.001 0.001
7 0 2 1000 3.823 0.002 0.491 0.010 0.007
8 0 2 5000 3.426 0.001 0.148 0.002 0.002
9 0 2 10000 3.182 0.000 0.101 0.001 0.001
10 1 0 1000 1.010 1.004 1.330 1.006 1.007
11 1 0 5000 1.002 1.002 1.092 1.004 1.004
12 1 0 10000 1.001 0.999 1.044 1.003 1.001
13 1 1 1000 3.906 0.997 1.422 1.016 1.010
14 1 1 5000 3.712 1.003 1.113 1.003 1.002
15 1 1 10000 3.581 1.001 1.082 1.002 1.002
16 1 2 1000 8.741 1.001 1.569 1.020 1.015
17 1 2 5000 8.134 0.998 1.166 1.000 0.999
18 1 2 10000 7.737 1.000 1.145 0.999 0.999
19 2 0 1000 3.999 3.989 4.206 3.977 3.984
20 2 0 5000 3.999 4.001 4.088 4.004 4.004
21 2 0 10000 3.995 3.994 4.059 4.003 4.003
22 2 1 1000 8.852 4.004 4.477 4.015 4.004
23 2 1 5000 8.567 3.998 4.152 3.997 3.998
24 2 1 10000 8.356 4.000 4.104 4.007 4.008
25 2 2 1000 15.583 3.999 4.760 4.007 4.005
26 2 2 5000 14.851 4.000 4.192 4.008 4.010
27 2 2 10000 14.298 4.002 4.134 4.005 4.004
28 3 0 1000 9.007 9.001 9.138 9.038 9.019
29 3 0 5000 9.006 9.000 9.122 8.997 9.000
30 3 0 10000 8.998 9.003 9.040 9.004 9.007
31 3 1 1000 15.854 8.995 9.593 9.007 9.012
32 3 1 5000 15.420 9.010 9.161 9.003 9.007
33 3 1 10000 15.135 9.002 9.049 8.998 8.999
34 3 2 1000 24.514 9.000 9.659 9.004 9.005
35 3 2 5000 23.505 8.992 9.286 9.005 9.005
36 3 2 10000 22.869 9.003 9.271 9.005 9.005
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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Binary outcome simulation study
Data generation
We run a factorial experiment using 2 cohort sample sizes (N) × 3 trial participant
proportions (Pr[S = 1]) × 4 main treatment effects (τ) × 3 magnitudes of departure
from additive effects (ψ), resulting in a total of 72 scenarios for the binary outcome
simulation study. Baseline covariate data generation, sample size choices, and the model
for selection into the trial had the same set-up as the continuous outcome simulation
study. We generated binary outcomes using a linear logistic outcome model:
logitPr[Yi = 1|Xi, Ai] = τAi + ψX1,iAi +Xiζ,
where ζT = (0, 1, 1, 1). Recall that τ is the main effect of treatment and ψ determines
the magnitude of effect modification by X1. We run scenarios with ψ = (0, 0.5, 1) and τ
values chosen to produce marginal odds ratios of (0.5, 0.75, 0.9, 1). Specifically, we used
the numerical methods described by Austin & Stafford [48] to determine the τ value
that resulted in the desired marginal odds ratio (see Appendix Table A.7 for the values
we used). In each simulated dataset we applied a trial-only estimator, along with the
estimators in Equations (1) through (4). All working models required for the different
estimators were correctly specified. We estimated bias, variance, and mean squared
error over 1000 runs for each scenario.
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Table A.7: Conditional and marginal treatment effects for the binary outcome simulation
study.
Marginal
OR τ ψ
0.9 -0.1981506 1
0.9 -0.1771545 0.5
0.9 -0.1602783 0
0.75 -0.5403137 1
0.75 -1.157093 0.5
0.75 -1.047368 0
0.5 -1.293645 1
0.5 -1.157093 0.5
0.5 -1.047368 0
OR = odds ratio.
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Results for binary outcome simulation study
Table A.8: Bias of estimators across different main treatment effects (τ), magnitudes of effect
modification (ψ), and trial sample sizes (n), for the binary outcome with N = 100, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0.5 0 1000 0.031 0.014 0.043 0.022 0.020
2 0.5 0 5000 0.041 0.002 0.003 0.002 0.002
3 0.5 0 10000 0.043 0.002 0.006 0.003 0.003
4 0.5 0.5 1000 0.027 0.015 0.057 0.024 0.024
5 0.5 0.5 5000 0.010 0.001 0.009 0.001 0.001
6 0.5 0.5 10000 0.003 0.001 0.005 0.002 0.002
7 0.5 1 1000 0.057 0.007 0.047 0.017 0.016
8 0.5 1 5000 0.034 0.002 0.004 0.002 0.002
9 0.5 1 10000 0.023 0.001 0.004 0.001 0.002
10 0.75 0 1000 0.016 0.022 0.087 0.049 0.041
11 0.75 0 5000 0.033 0.001 0.008 0.000 0.000
12 0.75 0 10000 0.030 0.002 0.009 0.001 0.001
13 0.75 0.5 1000 0.070 0.004 0.056 0.011 0.009
14 0.75 0.5 5000 0.056 0.000 0.006 0.002 0.003
15 0.75 0.5 10000 0.047 0.002 0.005 0.002 0.002
16 0.75 1 1000 0.128 0.007 0.073 0.015 0.012
17 0.75 1 5000 0.099 0.001 0.016 0.002 0.003
18 0.75 1 10000 0.084 0.001 0.010 0.003 0.002
19 0.9 0 1000 0.003 0.025 0.115 0.043 0.046
20 0.9 0 5000 0.013 0.005 0.029 0.010 0.009
21 0.9 0 10000 0.013 0.003 0.004 0.003 0.003
22 0.9 0.5 1000 0.136 0.027 0.093 0.034 0.031
23 0.9 0.5 5000 0.099 0.001 0.013 0.001 0.001
24 0.9 0.5 10000 0.088 0.001 0.004 0.002 0.002
25 0.9 1 1000 0.194 0.011 0.095 0.031 0.027
26 0.9 1 5000 0.156 0.003 0.013 0.002 0.002
27 0.9 1 10000 0.136 0.001 0.003 0.003 0.003
28 1 0 1000 0.026 0.031 0.128 0.049 0.042
29 1 0 5000 0.008 0.008 0.027 0.012 0.012
30 1 0 10000 0.001 0.002 0.009 0.002 0.003
31 1 0.5 1000 0.173 0.021 0.133 0.044 0.038
32 1 0.5 5000 0.136 0.002 0.017 0.003 0.003
33 1 0.5 10000 0.123 0.001 0.008 0.003 0.003
34 1 1 1000 0.240 0.022 0.142 0.040 0.040
35 1 1 5000 0.204 0.003 0.026 0.007 0.006
36 1 1 10000 0.177 0.000 0.004 0.000 0.000
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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Table A.9: Variance of estimators across different main treatment effects (τ), magnitudes of
effect modification (ψ), and trial sample sizes (n), for the binary outcome with N = 100, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0.5 0 1000 0.007 0.012 0.058 0.019 0.019
2 0.5 0 5000 0.001 0.002 0.008 0.003 0.003
3 0.5 0 10000 0.000 0.001 0.004 0.001 0.001
4 0.5 0.5 1000 0.008 0.010 0.062 0.022 0.018
5 0.5 0.5 5000 0.001 0.002 0.008 0.003 0.003
6 0.5 0.5 10000 0.001 0.001 0.003 0.001 0.001
7 0.5 1 1000 0.009 0.009 0.057 0.016 0.016
8 0.5 1 5000 0.001 0.001 0.008 0.002 0.002
9 0.5 1 10000 0.001 0.001 0.003 0.001 0.001
10 0.75 0 1000 0.016 0.026 0.153 0.124 0.048
11 0.75 0 5000 0.003 0.004 0.025 0.008 0.007
12 0.75 0 10000 0.001 0.002 0.009 0.003 0.003
13 0.75 0.5 1000 0.024 0.025 0.139 0.041 0.041
14 0.75 0.5 5000 0.004 0.004 0.018 0.006 0.005
15 0.75 0.5 10000 0.002 0.001 0.009 0.002 0.002
16 0.75 1 1000 0.026 0.024 0.156 0.037 0.036
17 0.75 1 5000 0.004 0.003 0.020 0.006 0.005
18 0.75 1 10000 0.002 0.001 0.010 0.002 0.002
19 0.9 0 1000 0.031 0.040 0.274 0.078 0.085
20 0.9 0 5000 0.005 0.006 0.031 0.009 0.009
21 0.9 0 10000 0.002 0.003 0.012 0.004 0.004
22 0.9 0.5 1000 0.039 0.041 0.244 0.068 0.065
23 0.9 0.5 5000 0.006 0.006 0.030 0.009 0.009
24 0.9 0.5 10000 0.003 0.002 0.012 0.004 0.004
25 0.9 1 1000 0.044 0.035 0.227 0.062 0.061
26 0.9 1 5000 0.007 0.006 0.031 0.010 0.010
27 0.9 1 10000 0.003 0.002 0.011 0.004 0.003
28 1 0 1000 0.037 0.052 0.269 0.093 0.089
29 1 0 5000 0.006 0.008 0.043 0.014 0.014
30 1 0 10000 0.003 0.003 0.015 0.005 0.005
31 1 0.5 1000 0.055 0.045 0.321 0.093 0.082
32 1 0.5 5000 0.008 0.007 0.042 0.012 0.012
33 1 0.5 10000 0.003 0.003 0.015 0.004 0.004
34 1 1 1000 0.059 0.044 0.308 0.076 0.071
35 1 1 5000 0.011 0.007 0.042 0.011 0.011
36 1 1 10000 0.004 0.003 0.014 0.005 0.005
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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Table A.10: Mean square error of estimators across different main treatment effects (τ),
magnitudes of effect modification (ψ), and trial sample sizes (n), for the binary outcome
with N = 100, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0.5 0 1000 0.227 0.276 0.353 0.291 0.290
2 0.5 0 5000 0.212 0.254 0.260 0.255 0.255
3 0.5 0 10000 0.209 0.252 0.260 0.255 0.255
4 0.5 0.5 1000 0.285 0.275 0.372 0.297 0.292
5 0.5 0.5 5000 0.261 0.252 0.267 0.254 0.254
6 0.5 0.5 10000 0.254 0.252 0.259 0.254 0.254
7 0.5 1 1000 0.319 0.267 0.356 0.283 0.282
8 0.5 1 5000 0.287 0.254 0.262 0.254 0.254
9 0.5 1 10000 0.274 0.252 0.257 0.252 0.253
10 0.75 0 1000 0.554 0.622 0.854 0.762 0.675
11 0.75 0 5000 0.518 0.568 0.600 0.571 0.570
12 0.75 0 10000 0.519 0.568 0.585 0.568 0.568
13 0.75 0.5 1000 0.697 0.594 0.789 0.620 0.617
14 0.75 0.5 5000 0.653 0.567 0.590 0.572 0.573
15 0.75 0.5 10000 0.637 0.567 0.578 0.568 0.568
16 0.75 1 1000 0.797 0.597 0.834 0.622 0.618
17 0.75 1 5000 0.725 0.568 0.606 0.572 0.572
18 0.75 1 10000 0.698 0.566 0.588 0.569 0.569
19 0.9 0 1000 0.847 0.897 1.305 0.968 0.982
20 0.9 0 5000 0.791 0.825 0.893 0.836 0.835
21 0.9 0 10000 0.789 0.817 0.830 0.819 0.819
22 0.9 0.5 1000 1.113 0.900 1.230 0.941 0.933
23 0.9 0.5 5000 1.004 0.817 0.864 0.822 0.821
24 0.9 0.5 10000 0.980 0.814 0.829 0.817 0.817
25 0.9 1 1000 1.240 0.866 1.218 0.929 0.921
26 0.9 1 5000 1.122 0.822 0.864 0.824 0.824
27 0.9 1 10000 1.075 0.813 0.827 0.819 0.819
28 1 0 1000 1.090 1.114 1.542 1.193 1.175
29 1 0 5000 1.022 1.025 1.098 1.038 1.037
30 1 0 10000 1.004 1.006 1.034 1.010 1.010
31 1 0.5 1000 1.431 1.089 1.604 1.183 1.160
32 1 0.5 5000 1.300 1.012 1.078 1.019 1.020
33 1 0.5 10000 1.266 1.005 1.031 1.010 1.010
34 1 1 1000 1.599 1.089 1.612 1.159 1.152
35 1 1 5000 1.462 1.014 1.095 1.026 1.024
36 1 1 10000 1.390 1.002 1.022 1.005 1.005
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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Table A.11: Bias of estimators across different main treatment effects (τ), magnitudes of ef-
fect modification (ψ), and trial sample sizes (n), for the binary outcome with N = 1, 000, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0.5 0 1000 0.031 0.007 0.043 0.017 0.015
2 0.5 0 5000 0.036 0.001 0.005 0.001 0.001
3 0.5 0 10000 0.036 0.002 0.010 0.004 0.003
4 0.5 0.5 1000 0.036 0.014 0.051 0.023 0.020
5 0.5 0.5 5000 0.022 0.001 0.003 0.002 0.002
6 0.5 0.5 10000 0.022 0.001 0.003 0.001 0.000
7 0.5 1 1000 0.061 0.009 0.040 0.016 0.014
8 0.5 1 5000 0.048 0.001 0.001 0.000 0.000
9 0.5 1 10000 0.051 0.001 0.005 0.001 0.001
10 0.75 0 1000 0.020 0.022 0.095 0.039 0.040
11 0.75 0 5000 0.029 0.001 0.008 0.004 0.003
12 0.75 0 10000 0.027 0.001 0.008 0.004 0.004
13 0.75 0.5 1000 0.087 0.015 0.052 0.021 0.021
14 0.75 0.5 5000 0.070 0.005 0.010 0.006 0.006
15 0.75 0.5 10000 0.072 0.001 0.014 0.004 0.005
16 0.75 1 1000 0.139 0.020 0.056 0.025 0.025
17 0.75 1 5000 0.117 0.004 0.010 0.005 0.005
18 0.75 1 10000 0.121 0.001 0.014 0.004 0.004
19 0.9 0 1000 0.009 0.032 0.121 0.059 0.050
20 0.9 0 5000 0.014 0.002 0.007 0.001 0.001
21 0.9 0 10000 0.015 0.001 0.021 0.005 0.005
22 0.9 0.5 1000 0.133 0.025 0.127 0.044 0.047
23 0.9 0.5 5000 0.111 0.001 0.011 0.005 0.004
24 0.9 0.5 10000 0.113 0.002 0.011 0.006 0.006
25 0.9 1 1000 0.204 0.028 0.084 0.036 0.036
26 0.9 1 5000 0.176 0.006 0.015 0.008 0.008
27 0.9 1 10000 0.180 0.001 0.018 0.004 0.005
28 1 0 1000 0.027 0.036 0.141 0.066 0.057
29 1 0 5000 0.001 0.002 0.009 0.001 0.001
30 1 0 10000 0.001 0.000 0.024 0.004 0.004
31 1 0.5 1000 0.169 0.030 0.153 0.059 0.058
32 1 0.5 5000 0.146 0.002 0.014 0.007 0.006
33 1 0.5 10000 0.148 0.003 0.015 0.005 0.006
34 1 1 1000 0.252 0.027 0.096 0.035 0.035
35 1 1 5000 0.223 0.007 0.017 0.009 0.009
36 1 1 10000 0.227 0.002 0.024 0.006 0.007
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
42
Table A.12: Variance of estimators across different main treatment effects (τ), magnitudes
of effect modification (ψ), and trial sample sizes (n), for the binary outcome with N =
1, 000, 000.
scenario τ ψ n Trial OM IPW DR1 DR2
1 0.5 0 1000 0.008 0.013 0.072 0.024 0.024
2 0.5 0 5000 0.001 0.001 0.006 0.002 0.002
3 0.5 0 10000 0.001 0.002 0.022 0.004 0.004
4 0.5 0.5 1000 0.010 0.012 0.086 0.022 0.020
5 0.5 0.5 5000 0.001 0.001 0.005 0.002 0.002
6 0.5 0.5 10000 0.002 0.002 0.012 0.004 0.003
7 0.5 1 1000 0.012 0.011 0.071 0.017 0.017
8 0.5 1 5000 0.001 0.001 0.005 0.001 0.001
9 0.5 1 10000 0.002 0.002 0.011 0.003 0.003
10 0.75 0 1000 0.018 0.029 0.275 0.061 0.057
11 0.75 0 5000 0.002 0.002 0.013 0.004 0.004
12 0.75 0 10000 0.003 0.005 0.032 0.009 0.009
13 0.75 0.5 1000 0.028 0.029 0.158 0.052 0.048
14 0.75 0.5 5000 0.002 0.002 0.014 0.004 0.004
15 0.75 0.5 10000 0.005 0.005 0.030 0.008 0.008
16 0.75 1 1000 0.033 0.030 0.162 0.052 0.048
17 0.75 1 5000 0.002 0.002 0.014 0.004 0.004
18 0.75 1 10000 0.006 0.004 0.030 0.008 0.008
19 0.9 0 1000 0.036 0.051 0.281 0.143 0.082
20 0.9 0 5000 0.003 0.004 0.021 0.006 0.006
21 0.9 0 10000 0.006 0.008 0.046 0.015 0.015
22 0.9 0.5 1000 0.044 0.043 0.421 0.079 0.082
23 0.9 0.5 5000 0.004 0.004 0.021 0.006 0.006
24 0.9 0.5 10000 0.008 0.007 0.050 0.012 0.012
25 0.9 1 1000 0.052 0.047 0.258 0.077 0.073
26 0.9 1 5000 0.004 0.003 0.021 0.006 0.005
27 0.9 1 10000 0.009 0.007 0.045 0.011 0.011
28 1 0 1000 0.049 0.068 0.365 0.186 0.111
29 1 0 5000 0.004 0.004 0.026 0.008 0.008
30 1 0 10000 0.008 0.010 0.059 0.019 0.018
31 1 0.5 1000 0.061 0.056 0.535 0.133 0.107
32 1 0.5 5000 0.005 0.005 0.027 0.008 0.008
33 1 0.5 10000 0.010 0.009 0.065 0.017 0.016
34 1 1 1000 0.068 0.057 0.327 0.099 0.092
35 1 1 5000 0.005 0.004 0.027 0.007 0.007
36 1 1 10000 0.012 0.009 0.057 0.015 0.014
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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Table A.13: Mean square error of estimators across different main treatment effects (τ),
magnitudes of effect modification (ψ), and trial sample sizes (n), for the binary outcome
with N = 1, 000, 000.
Scenario τ ψ n Trial OM IPW DR1 DR2
1 0.5 0 1000 0.228 0.270 0.366 0.291 0.289
2 0.5 0 5000 0.216 0.252 0.261 0.252 0.252
3 0.5 0 10000 0.217 0.254 0.282 0.257 0.257
4 0.5 0.5 1000 0.298 0.276 0.390 0.295 0.290
5 0.5 0.5 5000 0.274 0.252 0.258 0.253 0.253
6 0.5 0.5 10000 0.275 0.254 0.266 0.254 0.254
7 0.5 1 1000 0.326 0.271 0.363 0.283 0.282
8 0.5 1 5000 0.302 0.252 0.256 0.251 0.252
9 0.5 1 10000 0.306 0.251 0.266 0.254 0.254
10 0.75 0 1000 0.552 0.626 0.989 0.684 0.681
11 0.75 0 5000 0.522 0.566 0.588 0.573 0.572
12 0.75 0 10000 0.526 0.566 0.606 0.566 0.565
13 0.75 0.5 1000 0.729 0.614 0.801 0.646 0.641
14 0.75 0.5 5000 0.674 0.573 0.592 0.575 0.575
15 0.75 0.5 10000 0.680 0.569 0.614 0.576 0.577
16 0.75 1 1000 0.823 0.623 0.811 0.652 0.649
17 0.75 1 5000 0.754 0.571 0.592 0.574 0.574
18 0.75 1 10000 0.764 0.568 0.614 0.576 0.577
19 0.9 0 1000 0.861 0.919 1.322 1.063 0.983
20 0.9 0 5000 0.788 0.810 0.843 0.818 0.818
21 0.9 0 10000 0.788 0.820 0.895 0.834 0.833
22 0.9 0.5 1000 1.111 0.899 1.477 0.971 0.979
23 0.9 0.5 5000 1.027 0.816 0.851 0.826 0.824
24 0.9 0.5 10000 1.033 0.813 0.881 0.812 0.811
25 0.9 1 1000 1.270 0.908 1.227 0.952 0.949
26 0.9 1 5000 1.162 0.824 0.857 0.830 0.829
27 0.9 1 10000 1.175 0.818 0.888 0.828 0.829
28 1 0 1000 1.104 1.141 1.667 1.323 1.228
29 1 0 5000 1.005 1.001 1.043 1.011 1.010
30 1 0 10000 1.006 1.011 1.108 1.027 1.027
31 1 0.5 1000 1.428 1.117 1.863 1.255 1.225
32 1 0.5 5000 1.319 1.009 1.056 1.022 1.020
33 1 0.5 10000 1.327 1.004 1.095 1.006 1.004
34 1 1 1000 1.637 1.112 1.529 1.171 1.163
35 1 1 5000 1.501 1.018 1.062 1.025 1.025
36 1 1 10000 1.518 1.014 1.105 1.026 1.028
Please refer to the legend of Appendix Table A.1 for definitions of abbreviations.
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